(MENAFNEditorial) Following on from the growing pressure to develop new antibiotics, SMi's 19th annual Superbugs & Superdrug's conference will return to Central London in just under three weeks' time with a dedicated spotlight on industry incentives.
Using a criteria which examines how deadly the bacteria is and whether new antibiotics to treat them are already in the pipeline, the World Health Organisation (WHO) recently released a list of drug resistant "priority pathogens" - 12 families of bacteria that pose the greatest threat to human health. The WHO said that it hoped the list would spur governments to put in place policies to incentivise the development of new drugs.* Source: http://www.telegraph.co.uk/science/2017/02/27/a/
The established industry summit on antimicrobial resistance will gather an audience of scientific pioneers and health experts at a significant time for leaders to collaborate and stem the surge of resistant infections.
The spotlight on industry incentives will feature a selection of keynote addresses on national research strategy, activities to facilitate drug development, funding opportunities and portfolio partnerships presented by government bodies including the FDA and BARDA.
Sumanthi Nambiar, Director of the Division of Anti-Infective Products at the FDA said,
"I bring a regulatory perspective to the meeting...we have published guidance, engaged in discussions with key stakeholders and engaged in public private partnerships."
Some of those who have confirmed to attend include:
Abbott Medical Optics | Aberdeen University | Achaogen | Actelion | AiCuris Anti-infective Cures | Alacrita | Allecra Therapeutics | Antabio | Arsanis Biosciences | Auspherix | BARDA | BioPharm Insight | Chemical Biology Ventures | Colzyx | Da Volterra | Danestat consulting | DeNovaMed | Discuva | Drugs for Neglected Diseases initiative (DNDi) | DSTL Porton Down | Eligo Bioscience | Evotec | FDA | GSK | John Innes Centre | JSC R-PHARM | King khaled eye specialist hospital | King's College London | KWS BioTest | Merck | MHRA | Micromyx | Motif Bio | Mrc Technology | Neem Biotech | Novabiotics | Novo AS | PHARMA OMNIUM | Phico Therapeutics | Prince Sultan Medical Military City | Procarta Biosystems | SA Pathology | Seventure Partners | Spero Therapeutics | St George's, University of London | Synthetic Biologics, Inc. | Tiber Creek Partners | TranScrip Partners | University College Cork | University of Cambridge | University of North Texas Health Science Center | X-Biotix Therapeutics | X-Chem | Zambon Spa
Further information is available at: www.superbugssuperdrugs.com
Superbugs & Superdrugs
20th & 21st March 2017
Copthorne Tara Hotel, London, UK
Sponsored by MSD and Synthetic Biologics, Inc
--- end ---
Contact Information:
For all media inquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email:
For delegate inquiries contact Fateja Begum on Tel: +44 (0)20 7827 6184 / Email:
For exhibition and sponsorship inquiries contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email:
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
MENAFN0703201700703196ID1095296518
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.